313348-27-5

Synonyms: CS-1874; LEXISCAN; CVT-3146; Regadenoson Impurity; Regadenoson Impurity 16; Regadenoson Impurity 18; Regadenoson(CVT-3146); 6-Amino-2-[4-(methylcarbamoyl)-1H-pyrazol-1-yl]purine-9-yl-beta-D-ribofuranoside Regadenoson; Regadenoson 6-Amino-2-[4-(methylcarbamoyl)-1H-pyrazol-1-yl]purine-9-yl-beta-D-ribofuranoside
Density: 1.98±0.1 g/cm3
Pka: 13.07±0.70
Solubility: DMSO (Slightly), Methanol (Slightly, Sonicated)
Refractive index: 1.896

Description:
Regadenoson is an injectable adenosine A2A receptor agonist for use as a pharmacologic stress agent in myocardial perfusion imaging (MPI) studies in patients unable to undergo adequate exercise induced stress. Regadenoson is the first adenosine A2A receptor agonist shown to be safe and effective as a pharmacologic stress agent in MPI studies. It is delivered as a rapid bolus (approximately 10 seconds) with no dose adjustment required for body weight.

Uses:
A selective A2A adenosine receptor agonist in myocardial imaging.
Regadenoson is a selective, short-acting adenosine A2A receptor agonist. Regadenoson is used to induce hyperemia (increased blood flow), particularly in the context of myocardial perfusion imaging. It has also been found to increase the delivery of compounds to the central nervous system through the blood-brain barrier in animals.
Regadenoson is a selective and potent A2A adenosine receptor agonist. The adenosine A2A receptor is a G-protein-coupled receptor and a key therapeutic target for oncologic, inflammatory, Parkinson''s and cardiovascular diseases. In rodent studies, it has been shown that co-administration of Regadenoson with Temozolomide (T017775) can increase Temozolomide concentration in the brain.